607 related articles for article (PubMed ID: 31164099)
21. Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation.
Ali MAM; Harmsen WS; Morsy KH; Galal GMK; Therneau TM; Roberts LR
BMC Cancer; 2022 Feb; 22(1):221. PubMed ID: 35227234
[TBL] [Abstract][Full Text] [Related]
22. Changes in serum alpha fetoprotein in patients with recurrent hepatocellular carcinoma following hepatectomy.
Liu G; Wang K; Li J; Xia Y; Lu L; Wan X; Yan Z; Shi L; Lau WY; Wu M; Shen F
J Gastroenterol Hepatol; 2015 Sep; 30(9):1405-11. PubMed ID: 25801981
[TBL] [Abstract][Full Text] [Related]
23. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database.
Ding J; Wen Z
BMC Cancer; 2021 Oct; 21(1):1157. PubMed ID: 34715816
[TBL] [Abstract][Full Text] [Related]
24. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
25. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
[TBL] [Abstract][Full Text] [Related]
26. Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection.
Tsai MC; Yen YH; Chang KC; Hung CH; Chen CH; Lin MT; Hu TH
BMC Cancer; 2019 Dec; 19(1):1169. PubMed ID: 31791275
[TBL] [Abstract][Full Text] [Related]
27. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma.
Xu MZ; Yao TJ; Lee NP; Ng IO; Chan YT; Zender L; Lowe SW; Poon RT; Luk JM
Cancer; 2009 Oct; 115(19):4576-85. PubMed ID: 19551889
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Role of Basal Serum Alpha-Fetoprotein in Patients with Hepatocellular Carcinoma Suitable for Curative Treatment.
Mazza S; Frigerio C; Alfieri D; Mauro A; Torello Viera F; Scalvini D; Barteselli C; Sgarlata C; Veronese L; Bardone M; Rovedatti L; Agazzi S; Strada E; Pozzi L; Maestri M; Ravetta V; Anderloni A
Medicina (Kaunas); 2024 Apr; 60(5):. PubMed ID: 38792876
[No Abstract] [Full Text] [Related]
29. Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
Chan SL; Mo F; Johnson P; Li L; Tang N; Loong H; Chan AW; Koh J; Chan AT; Yeo W
J Gastroenterol Hepatol; 2015 Oct; 30(10):1529-35. PubMed ID: 25968302
[TBL] [Abstract][Full Text] [Related]
30. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma.
Bai DS; Zhang C; Chen P; Jin SJ; Jiang GQ
Sci Rep; 2017 Oct; 7(1):12870. PubMed ID: 28993684
[TBL] [Abstract][Full Text] [Related]
31. Tumor size as a prognostic factor in resected small hepatocellular carcinoma: a controversy revisited.
Chen YL; Ko CJ; Chien SY; Chen LS; Chen ML; Chi CW; Lai HW
J Gastroenterol Hepatol; 2011 May; 26(5):851-7. PubMed ID: 21129015
[TBL] [Abstract][Full Text] [Related]
32. Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database.
Zhang N; Gu J; Yin L; Wu J; Du MY; Ding K; Huang T; He X
Oncotarget; 2016 Dec; 7(49):81389-81401. PubMed ID: 27835609
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
[TBL] [Abstract][Full Text] [Related]
34. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
[TBL] [Abstract][Full Text] [Related]
35. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma.
Kato H; Yoshida H; Taniguch H; Nomura R; Sato K; Suzuki I; Nakata R
World J Gastroenterol; 2015 Dec; 21(46):13101-12. PubMed ID: 26673627
[TBL] [Abstract][Full Text] [Related]
36. Expression of serum miR-218 in hepatocellular carcinoma and its prognostic significance.
Yang L; Xu Q; Xie H; Gu G; Jiang J
Clin Transl Oncol; 2016 Aug; 18(8):841-7. PubMed ID: 26586116
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of γ-glutamyl transpeptidase to albumin ratio combined with aspartate aminotransferase to lymphocyte ratio in patients with hepatocellular carcinoma after hepatectomy.
Liu KJ; Lv YX; Niu YM; Bu Y
Medicine (Baltimore); 2020 Nov; 99(48):e23339. PubMed ID: 33235099
[TBL] [Abstract][Full Text] [Related]
38. King's score as a novel prognostic model for patients with hepatitis B-associated hepatocellular carcinoma.
Pang Q; Bi JB; Xu XS; Liu SS; Zhang JY; Zhou YY; Qu K; Liu C
Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1337-46. PubMed ID: 26275082
[TBL] [Abstract][Full Text] [Related]
39. Clinical Features and Outcome of Surgical Patients with Non-B Non-C Hepatocellular Carcinoma.
Wakiyama S; Matsumoto M; Haruki K; Gocho T; Sakamoto T; Shiba H; Futagawa Y; Ishida Y; Yanaga K
Anticancer Res; 2017 Jun; 37(6):3207-3213. PubMed ID: 28551666
[TBL] [Abstract][Full Text] [Related]
40. The Value of the C-Reactive Protein-to-Albumin Ratio is Useful for Predicting Survival of Patients with Child-Pugh Class A Undergoing Liver Resection for Hepatocellular Carcinoma.
Shimizu T; Ishizuka M; Suzuki T; Tanaka G; Shiraki T; Sakuraoka Y; Matsumoto T; Kato M; Aoki T; Kubota K
World J Surg; 2018 Jul; 42(7):2218-2226. PubMed ID: 29288307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
